Disclosures to ICD. Prior to execution of this CRADA, Collaborator agrees to disclose to ICD all instances in which outstanding royalties are due under a PHS license agreement and in which Collaborator had a PHS license terminated in accordance with 37 C.F.R. § 404.10. These disclosures will be treated as Confidential Information upon request by Collaborator in accordance with the definition in Article 2 and Paragraphs 8.3 and 8.4.
Appears in 14 contracts
Samples: And Development Agreement, Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR), Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR)
Disclosures to ICD. Prior to execution of this CRADA, Collaborator agrees to disclose to ICD all instances in which outstanding royalties are due under a PHS license agreement and in which Collaborator had a PHS license terminated in accordance with 37 C.F.R. § 404.10. These disclosures will be treated as Confidential Information upon request by Collaborator in accordance with the definition in Article 2 and Paragraphs 8.3 2.4, 8.3, and 8.4.
Appears in 4 contracts
Samples: Public Health Service, Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR), Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR)
Disclosures to ICD. Prior to execution of this CRADA, Collaborator Xxxxxxxxxxxx agrees to disclose to ICD all instances in which outstanding royalties are due under a PHS license agreement and in which Collaborator had a PHS license terminated in accordance with 37 C.F.R. § 404.10. These disclosures will be treated as Confidential Information upon request by Collaborator in accordance with the definition in Article 2 and Paragraphs 8.3 2.4, 8.3, and 8.4.
Appears in 3 contracts
Samples: Research and Development Agreement (Newlink Genetics Corp), Research and Development Agreement (Newlink Genetics Corp), Research and Development Agreement (Newlink Genetics Corp)
Disclosures to ICD. Prior to execution of this CRADA, Collaborator agrees to disclose to ICD all instances in which outstanding royalties are due under a PHS license agreement and in which Collaborator had a PHS license terminated in accordance with 37 C.F.R. § 404.10. These disclosures will be treated as Confidential Information upon request by Collaborator in accordance with the definition in Article 2 and Paragraphs 8.3 and 8.4.. PHS ECT-CRADA CRADA Ref. No.02663 MODEL ADOPTED June 18, 2009
Appears in 2 contracts
Samples: Agreement (Tracon Pharmaceuticals, Inc.), Agreement (Tracon Pharmaceuticals Inc)
Disclosures to ICD. Prior to execution of this CRADA, Collaborator agrees to disclose to ICD all instances in which outstanding royalties are due under a PHS license agreement agreement, and in which Collaborator had a PHS license terminated in accordance with 37 C.F.R. C.F .R. § 404.10. These disclosures will be treated as Confidential Information upon request by Collaborator in accordance with the definition in Article 2 and Paragraphs 8.3 2.4, 8.3, and 8.4.
Appears in 2 contracts
Samples: Agreement (SRKP 7 Inc), Public Health Service (Lixte Biotechnology Holdings, Inc.)
Disclosures to ICD. Prior to execution of this CRADA, Collaborator agrees to disclose to ICD all instances in which outstanding royalties are due under a PHS license agreement and in which Collaborator had a PHS license terminated in accordance with 37 C.F.R. § 404.10404.9. These PHS ICT-CRADA Model Adopted 2005 disclosures will be treated as Confidential Information upon request by Collaborator in accordance with the definition in Article 2 and Paragraphs 8.3 2.4, 8.3, and 8.4.
Appears in 1 contract
